Prothena Corporation (PRTA)
12.65
-0.48 (-3.66%)
At close: Jan 14, 2025, 3:59 PM
12.67
0.16%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 12.5 |
| Market Cap | 680.68M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.46 |
| PE Ratio (ttm) | -5.14 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 15.25 |
| Volume | 497,974 |
| Avg. Volume (20D) | 559,993 |
| Open | 13.36 |
| Previous Close | 13.13 |
| Day's Range | 12.41 - 13.41 |
| 52-Week Range | 11.70 - 34.90 |
| Beta | undefined |
About PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2012
Employees 173
Stock Exchange NASDAQ
Ticker Symbol PRTA
Website https://www.prothena.com
Analyst Forecast
According to 7 analyst ratings, the average rating for PRTA stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 247.83% from the latest price.
Buy 71.43%
Hold 28.57%
Sell 0.00%
Next Earnings Release
Prothena Corporation is scheduled to release its earnings on Feb 13, 2025,
during market hours.
Analysts project revenue of $7.53M, reflecting a 2.28K% YoY growth and earnings per share of -1.04, making a -17.46% decrease YoY.
Analysts project revenue of $7.53M, reflecting a 2.28K% YoY growth and earnings per share of -1.04, making a -17.46% decrease YoY.
3 weeks ago ·
Source
+33.97%
Prothena shares are trading higher after the Phase...
Unlock content with
Pro Subscription
5 months ago ·
Source
+4.42%
Prothena shares are trading higher after the company reported better-than-expected Q2 financial results.
